Spark Therapeutics Inc is a United States based company operating in the field of gene therapy. It is focused on debilitating genetic diseases by developing one-time, life-altering treatments. The company's product candidates are in the field of retina-directed gene therapies, liver-directed gene therapies, and central nervous system therapies. The entity's key product, LUXTURNA, is for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation-associated retinal dystrophy. It generates revenue primarily from the license and collaborative agreements.
No Data